Amgen (AMGN) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Amgen (AMGN) over the past year, gaining 293.4% versus a gain of 38.3%. Over five years, RVMD leads with a +598.0% price change compared with +96.0% for AMGN. Amgen is the larger company by market cap ($220.28 billion vs $40.32 billion), about 5.5 times the size.
Amgen pays a dividend yielding 2.41%, while Revolution Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | RVMD |
|---|---|---|
| Share price | $407.44 | $188.12 |
| Market cap | $220.28B | $40.32B |
| 1-day change | -1.37% | -6.35% |
| YTD return | +24.48% | +136.18% |
| 1-year return | +38.29% | +293.39% |
| 5-year return | +96.04% | +598.03% |
| P/E ratio (TTM) | 25.31 | — |
| Forward P/E | 16.64 | — |
| EPS (TTM) | $16.10 | $-8.87 |
| Dividend yield | 2.41% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | $0 |
| Revenue growth (YoY) | +9.95% | — |
| Net income (latest FY) | $7.71B | $-1.13B |
| Gross margin | 67.25% | — |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | — |
| 52-week high | $447.03 | $224.31 |
| 52-week low | $288.00 | $47.28 |
| Distance from 52-week high | -8.86% | -16.13% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -3.92% | +37.59% |
| Average volume | 2.73M | 1.88M |
| Shares outstanding | 540.63M | 214.34M |
| Employees | 31,500 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 5.5 times larger than Revolution Medicines by market value ($220.28B vs $40.32B).
- RVMD has outperformed AMGN by 255.1 percentage points over the past year.
- Amgen offers a meaningfully higher dividend yield (2.41% vs 0.00%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
AMGN vs RVMD FAQ
Which is bigger, Amgen or Revolution Medicines?
Amgen (AMGN) is larger, with a market capitalization of $220.28B compared with $40.32B for Revolution Medicines (RVMD).
Which stock has performed better over the past year, AMGN or RVMD?
RVMD returned +293.39% over the past 12 months, compared with +38.29% for AMGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amgen or Revolution Medicines?
Amgen pays a dividend yielding 2.41%, while Revolution Medicines does not currently pay a regular dividend.
Are Amgen and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.